Research
Hormonal
SGLT2 receptor inhibitors (SGLT2R-i) provide significant cardiovascular and renal benefits, including reduced cardiovascular mortality and heart failure hospitalization, in addition to glycaemic control, by preventing glucose reabsorption in the kidneys.
SGLT2 inhibitors (like empagliflozin or dapagliflozin) are powerful drugs for T2DM patients with heart or kidney risks. They significantly reduce heart failure hospitalizations and mortality. Maintain good hygiene to minimize the risk of genital infections.
StrongSupportsVERY_HIGH confidence
They gained prominence when the EMPA-Reg trial in 2015, using empagliflozin with standard care in patients with T2DM at high risk of cardiovascular events, showed a relative risk reduction (RRR) of 38% in cardiovascular mortality, 35% RRR in heart failure hospitalisation (HFH) and 32% RRR in all-cause mortality
Why this rating
Supported by major trials (EMPA-Reg, DECLARE-TIMI 58, DAPA-HF, EMPEROR Reduced).
Source
Management of Type 2 Diabetes Mellitus
Leslie Bahn Kawa · IntechOpen eBooks · 2023
book_chapterCited 5×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →